Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell

BACKGROUND: Colorectal cancer is the second commonly seen cancer around the world and accounts for 13% of all human cancers. Among them, 25% of all case were diagnosed with metastasis and 50% occurs metastasis during the development of disease. Cetuximab is a chimeric monoclonal antibody against epi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiaohui, Wang, Shuai, Yu, Weihua, Zheng, Yixiong, Wu, Yulian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337548/
https://www.ncbi.nlm.nih.gov/pubmed/32629699
http://dx.doi.org/10.1097/MD.0000000000020944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337548/
https://www.ncbi.nlm.nih.gov/pubmed/32629699
http://dx.doi.org/10.1097/MD.0000000000020944

Ejemplares similares